Doses of 13-valent conjugated pneumococcal vaccine (PCV13) for patients with multiple myeloma (MM)
Background: Patients with MM are
vulnerable to bacterial infection, especially invasive pneumococcal diseases.
Vaccination with 1-dose PCV13 is recommended, but their poor immunogenicity was
observed. We aimed to assess whether 2-dose PCV13 might help.
Methods: Patients with MM were randomized to receive 1- or 2- dose PCV13. The 2 doses were given 1 month apart. Measurements of antibody to the four most common serotypes 6B, 14, 19F, and 23F pre-vaccination, 1, 3, 6, 9, and 12 months after the last dose of PCV13 were performed. Achievement of significant antibody response was defined as ≥2-fold increase in the IgG level.
Results: From Jan 2016 to Dec 2017, a total of 72 patients were randomized to receive 1- (n=35) or 2-doses (n=37) PCV13. Of all, 31 patients (43%), including 1-dose in 14 and 2-dose in 17, had completed 12-month follow-up with a median age of 62 years old (IQR 54-66). Sequential changes of significant antibody responses to serotype 6B, 14, 19F, and 23F during 1-year follow-up in 1- and 2-does groups are presented in Figure 1. The proportions of significant antibody responses to serotype 6B, 14, 19F, and 23F after 1-year follow-up were 33.3%, 25.0%, 41.7%, and 41.7% in 1-dose group and 11.8%, 35.3%, 29.4%, and 23.5% in 2-dose group, respectively.
Conclusion: Two-dose PCV13 did not provide better immunogenicity to patients with MM. Innovative strategies to improve the immunogenicity of PCV13 in patients with MM are needed.
Figure 1: Sequential changes of significant antibody responses to serotype 6B, 14, 19F, and 23F during 1-year follow-up in 1- and 2-dose groups
H. Y. Sun,
S. Y. Huang, None
S. Y. Chang, None
Y. C. Chen, None
S. C. Chang, None